Pan Arab Journal of Oncology (PAJO) follows most of the uniform requirements for manuscript submission to biomedical journal of International Committee of Medical Journal Editors (ICMJE). Authors will find most of these recommendations in the following text to facilitate preparation of their manuscript.
Authorship and Contribution
An Author must take responsibility for at least one component of the work, should be able to identify who is responsible for each of other component, and should ideally be confident in their co-authors’ ability and integrity.
Authorship credit should be based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it clinically for important intellectual content; and (3) final approval of the version to be published. Author should meet conditions 1, 2, and3.
Potential Conflict of Interest
In compliance with standards established and implemented by ICMJE, it is the PAJO intent, to ensure balance, independence, objectivity, and scientific rigor in all of its editorial policies related to the Journal. Scientists have an ethical obligation to submit creditable research results for publications. Authors should describe the role of the study sponsor, if any, in study design: collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication.
All contributors to the Journal are required to disclose any financial and other relationships with entities that have investment, licensing, or other commercial interests in the subject matter under consideration in their article. These disclosures should include, but are not limited to, relationships with pharmaceutical and biotechnology companies, device manufacturers, or other corporations whose products or services are related to the subject matter of the submission. The corresponding author may complete the form on behalf of other authors, or authors may complete their own forms and forward them to the corresponding author. This information will be sent to the Editorial Board.
Privacy and Confidentiality
Patients have a right to privacy that should not be violated without informed consent. Clinical trials and research have to provide approval of ethical committee or institutional review board dated prior the start of study. Statement of informed consent must be included in manuscript and author provides PAJO with a written statement that he/she have received and achieved patients’ consents.
Protection of Human Subjects and Animals in Research
On including human subjects in clinical research author must indicate that study procedure followed the ethical standards of the institution and with the Helsinki Declaration revised on 2013. On reporting animal experiments, author should declare that institutional and national guides for care of experimental animals were followed.
PAJO is not accepting a manuscript simultaneously submitted to other journal. Author must declare to the editor (in the title page) any sort of previous presentation of the manuscript or the research (e.g. conference, scientific meeting, and posting results in registries) that might be redundant or duplicate submission
The Editor-in-Chief and an Associate Editor generally review Reports from clinical trials. Selected manuscripts are also reviewed by at least two external peer reviewers. Comments offered by reviewers are returned to the author(s) for consideration. Manuscript acceptance is based on many factors, including the importance of the research to the field of oncology and the quality of the study. Authors should focus on accuracy, clarity, and brevity in their presentation, and should avoid lengthy introductions, repetition of data from tables and figures in the text, and unfocused discussions. Extended patient demographic data should be included in a table, not listed within the text.
Clinical trials are recommended to be registered in clinical trial database and provide PAJO registration number. Reports of phase II & III studies should include from the protocol a clear definition of the primary end point, the hypothesized value of the primary end point that justified the planned sample size, and a discussion of possible weaknesses, such as comparison to historical controls.
Phase I studies will be well received if they have interesting clinical responses, unusual toxicity that pointed to mechanism of action of the agents, and important or novel correlative laboratory studies associated with the trials.
All reviews must be clinically oriented, i.e., at least half the review must describe studies that detail human impact, marker effect on prognosis, or clinical trials. Review Articles should be prepared in accordance with the Journal s Manuscript Preparation Guidelines, and will be reviewed in the same manner as Reports from Clinical Trials.
Editorials / Comments / Controversies
The Editor-in-Chief may solicit an Editorial to accompany an accepted manuscript. Authors who wish to submit unsolicited Comments and Controversies should contact the Editor-in-Chief, before submission to determine the appropriateness of the topic for publication in the Journal.
Articles on Health Economics
Articles about health economics (cost of disease, cost-effectiveness of drugs, etc.) are highly encouraged.
Case Reports / Correspondence / Special Articles
Correspondence (letters to the Editor) may be in response to a published article, or a short, free-standing piece expressing an opinion, describing a unique case, or reporting an observation that would not qualify as an Original Report. If the correspondence is in response to a published article, the Editor-in-Chief may choose to invite the article’s authors to write a Correspondence reply. Special Articles present reports, news from international, regional societies as well as news from our compatriots.
Manuscript submission procedure
The manuscript should adhere to the journal requirements. Upon manuscript submission, corresponding authors must provide unique e-mail addresses for all contributing authors. Receipt of manuscripts will be acknowledged via e-mail. Upon completion of editorial review, the corresponding author will receive notification of the Editors decision, along with the reviewers’ comments, as appropriate, via e-mail
Manuscript Preparation Guidelines
The first page of the manuscript must contain the following information: (1) title of the report, as succinct as possible; (12-50 words) (2) author list of no more than 20 names (first name, last name); (3) names of the authors institutions and an indication of each author s affiliation; (4) acknowledgments of research support or grant; (5) name, address, telephone and fax numbers, and e-mail address of the corresponding author; (6) running head of no more than 50 characters (including spaces); (7) list of where and when the study has been presented in part elsewhere, if applicable; (8) disclaimers (conflict of interest, informed consent of patients and Human and animal rights protection) (9) Word count of text only and (10) number of tables and figures.
Abstracts must appear after the title page. Abstracts must be formatted according to the following headings: (1) Purpose, (2) Patients and methods (or materials and methods, similar heading), (3) Results, and (4) Conclusion. Authors may use design instead of Patients and methods in abstracts of Review Articles. Articles on clinical trials should contain abstract that include the items of CONSORT group (http://www.consort-statement.org/ consort-statement)
All submissions must include abstracts except comments and controversies, Editorials, Correspondence and book review.
Abstracts should not contain citations, figures or tables.
A list of key words should be provided and not more than 8 in alphabetical order below the abstract.
The maximum length of an article, exclusive of tables, figures, references and abstract, should be as follows:
Original article 3000 words
Review article 4500 words
Editorial, Comments and Controversies 3000 words
Health economics 2000 words
Case report 2000 words
Letter to editor 600 words
Abstract 250 words
Authors must provide a word count for both abstract and the text.
The body of the manuscript should be written as concisely as possible and must not exceed the manuscript category word limits described herein. All pages of a submission should be numbered and double-spaced. Times Roman and Arial at 12 points size are the recommended fonts for all text (see Figures section for acceptable fonts for figures). The Journal adheres to the style guidelines set forth by the International Committee of Medical Journal Editors
Describe statistical methods with enough details to enable a knowledgeable reader with access to original data to verify the reported results. Use P as upper case letter and italic. Avoid reporting an excessive number of digits beyond the decimal. Indicate whether P value are one sided or two sided.
Try to limit use of abbreviations. Abbreviation used for first time must be in between parentheses. Abbreviations may be used in tables and figures and defined in legends. Avoid use of abbreviation solely to limit the word count.
Use Greek letters in text rather than spelled out words whenever possible (e.g. use a instead of alpha).
Don’t use footnotes in the text
Use Arabic numbers and use comma in numbers 4 or more digits
Use the metric system of all measurements for length, height and volume, etc. (e.g. temperature in degrees Celsius, Blood pressure should be in millimeters of mercury)
References must be listed and numbered after the body text in the order in which they are cited in the text. They should be double-spaced and should appear under the heading REFERENCES. Abbreviations of medical periodicals should conform to those used in the latest edition of Index Medicus and on MEDLINE. The List of Journals Indexed in Index Medicus includes the latest abbreviations. Inclusive page numbers must be cited in the reference. When a reference is for an abstract or supplement, it must be identified as such in parentheses at the end of the reference. Abstract and supplement numbers should be provided, if applicable. When a reference is a personal communication, unpublished data, a manuscript in preparation, or a manuscript submitted but not in press, it should be included in parentheses in the body of the text, and not cited in the reference list. Published manuscripts and manuscripts that have been accepted and are pending publication should be cited in the reference list.
- Journal article with one, two, or three authors
Dolan ME, Pegg AE: O6-Benzylguanine and its role in chemotherapy. Clin Cancer Res 8:837-847, 1997
- Journal article with more than three authors
Knox S, Hoppe RT, Maloney D, et al: Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 87:893-899, 1996
- Journal article in press (manuscript has been accepted for publication)
Scadden DT, Schenkein DP, Bernstein Z, et al: Combined immunotoxin and chemotherapy for AIDS-related non-Hodgkin s lymphoma. Cancer (in press)
Brusamolino E, Orlandi E, Morra E, et al: Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin s disease treated with the alternating MOPP/ABVD chemotherapy. Ann Oncol 5:S53-S57, 1994 (suppl 2)
- Book with a single author
Woodruff R: Symptom Control in Advanced Cancer. Victoria, Australia, Asperula Pty Ltd, 1997, pp 65-69
- Book with multiple authors
Iverson C, Flanagin A, Fontanarosa PB, et al: American Medical Association Manual of Style (ed 9). Baltimore, MD, Williams & Wilkins, 1998
- Chapter in a multiple authored book with editors
Seykora JT, Elder DE: Common acquired navi and dysplastic nevi as precursor lesions and risk markers of melanoma, in Kirkwood JM (ed): Molecular Diagnosis and Treatment of Melanoma. New York, NY, Marcel Dekker, 1998, pp 55-86
Bardia A, Wang AH, Hartmann LC, et al: Physical activity and risk of postmenopausal breast cancer defined by hormone receptor status and histology: A large prospective cohort study with 18 years of follow up. J Clin Oncol 24:49s, 2006 (suppl; abstr 1002)
Kaplan EH, Jones CM, Berger MS: A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab refractory metastatic breast cancer. Proc Am Soc Clin Oncol 22:245, 2003 (abstr 981)
- Conference/meeting presentation
Dupont E, Riviere M, Latreille J, et al: Neovastat: An inhibitor of angiogenesis with anti-cancer activity. Presented at the American Association of Cancer Research Special Conference on Angiogenesis and Cancer, Orlando, FL, January 24-28, 1998
- Internet resource
Health Care Financing Administration: Bureau of data management and strategy from the 100% MEDPAR inpatient hospital fiscal year 1994: All inpatients by diagnosis related groups, 6/95 update. http://www.hcfa.gov/a1194drg.txt
- Digital Object Identifier (DOI)
Small EJ, Smith MR, Seaman JJ, et al: Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 10.1200/JCO.2003.05.147
- Government Announcement/Publication
Miller BA, Ries CAG, Hankey BF, et al (eds): Cancer Statistics Review: 1973-1989. Bethesda, MD, National Cancer Institute, NIH publication No. 92-2789, 1992
- ASCO Educational Book
Benson AB 3rd: Present and future role of prognostic and predictive markers for patients with colorectal cancer. Am Soc Clin Oncol Ed Book 187-190, 2006
PAJO accept 3 figures per manuscript (6 figures and tables per manuscript). Figures must be cited in the order they appear in the text using Arabic numerals. Figures should be submitted in a separate document. Accepted figures formats are pdf, eps, jpg. Figure legends are required for all article types. Figure legends must not exceed 55 words per figure and should be written below the figure in double space. Images may be embedded in word or PowerPoint files. Figures will be reduced to fit one column or two column width of the journal page so letters, numbers, decimal points and symbols in figures should be clear and at least of 10 point size font.
PAJO accept 3 tables per manuscript (6 figures and tables per manuscript). Tables must be cited in the order in which they appear in the text using Arabic numerals. Table should be typed in Microsoft word with double spaces on separate pages. Tables numbered in Arial font 12 points e.g. Table 1. Then table title. Table title must not exceed 20 words. The table’s footnote may include any pertinent notes and must include definitions of all abbreviations and acronyms that have been used in the table. Footnote must not exceed 55 words per table. Tables submitted with multiple parts will be renumbered
Appendices and acknowledgments will appear in the print version of the article after text and before references.
Acknowledgment provides a list that may include: (1) Author affiliation, (2) statement about author contribution, (3) Grant and/or financial support. (4) Thanks and (5) members of the study.
Appropriate use of the English language is encouraged for publication in the Journal.
Corresponding authors must provide unique e-mail address for each contributing author at manuscript submission. Upon acceptance of the manuscript, each author will receive an e-mail invitation to sign a statement confirming that the manuscript contains no material for which publication would violate any copyright or other personal or proprietary right of any person or entity. Manuscripts will not be published until each author has completed the form.
Corresponding author will receive proofs and must carefully review them for data and typesetting errors. Corrections to proofs must be returned by e-mail within One week. The corresponding author is responsible for collecting and submitting all author corrections into a single submission. Publication may be delayed if proofs are not returned by the publisher s deadline. The Editor-in-Chief must approve all major alterations, which may delay publication of the manuscript.